United States Hereditary Angioedema Therapeutics Market: Size, trend and growth (2025-2034)

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the face, extremities, gastrointestinal tract, and upper respiratory tract. These episodes can be life-threatening, especially when they affect the airway. In the United States, the hereditary angioedema therapeutics market is experiencing significant growth, driven by advancements in treatment options, a favorable regulatory environment, and increased awareness of the condition. As novel therapies continue to emerge and patient access to treatment improves, the market is expected to grow at a compound annual growth rate (CAGR) of 8.20% from 2025 to 2034.

Get a free sample report: https://shorturl.at/Z7a69

Market Overview

Hereditary angioedema is caused by a deficiency or dysfunction of C1-inhibitor, a protein that regulates the complement system and helps control inflammation. HAE attacks can be unpredictable and are typically triggered by factors such as stress, trauma, or hormonal changes. Without proper treatment, the swelling episodes can lead to serious complications, including airway obstruction, which can be fatal. As a result, effective treatment options are crucial for patients suffering from HAE. The therapeutic landscape for hereditary angioedema has evolved significantly in recent years, with multiple treatments now available that aim to reduce the frequency and severity of attacks.

The U.S. hereditary angioedema therapeutics market is gaining momentum due to the rising number of HAE cases, a growing demand for targeted therapies, and the increasing approval of novel treatments. The availability of both preventive and on-demand treatments has improved the quality of life for patients, while an increasing awareness of the condition among both healthcare providers and patients is driving demand for more effective treatments. The U.S. market is expected to see substantial growth, driven by continued clinical innovations and the broadening of therapeutic options.

Read full report with table of content: https://shorturl.at/FGagc

Market Size and Share

The U.S. hereditary angioedema therapeutics market is currently valued at approximately USD 2.5 billion in 2024. This market is expected to grow at a robust CAGR of 8.20% during the forecast period from 2025 to 2034. By 2034, the market is projected to reach around USD 5.7 billion. The market's growth is fueled by the increased diagnosis of hereditary angioedema, the rise in available treatment options, and advancements in personalized therapies. As more patients gain access to specialized treatments, the demand for effective and convenient therapeutic solutions will further support market expansion.

Market Trends

Rising Focus on Novel Therapies: The development of novel therapies for hereditary angioedema is one of the primary trends driving the market. Researchers and pharmaceutical companies are focused on creating treatments that not only prevent HAE attacks but also offer faster relief from acute episodes. New drug classes such as kallikrein inhibitors and bradykinin B2 receptor antagonists are gaining traction in clinical settings due to their ability to address the root causes of HAE, offering significant improvements over older treatment options like C1-esterase inhibitors.

Increasing Regulatory Approvals: The regulatory environment for HAE treatments in the U.S. has become more favorable in recent years. The U.S. Food and Drug Administration (FDA) has approved several novel therapies for hereditary angioedema, including monoclonal antibodies and peptide inhibitors, which have contributed to the growth of the market. Fast-track approvals, breakthrough therapy designations, and orphan drug statuses are accelerating the availability of innovative treatments to patients, enabling faster market penetration and improved outcomes for individuals with HAE.

Rising Awareness and Diagnosis Rates: As awareness of hereditary angioedema grows, more patients are being diagnosed and treated. Improved diagnostic methods, including genetic testing and advanced biomarkers, allow for quicker identification of the condition, leading to earlier interventions and better management of the disease. Increased awareness among healthcare providers, coupled with enhanced patient advocacy efforts, has resulted in more individuals seeking medical attention, thereby driving the demand for targeted therapeutics.

Emphasis on Personalized Medicine: The trend toward personalized medicine is also gaining momentum in the hereditary angioedema therapeutics market. With advances in genetic testing, there is an increasing focus on developing therapies that are tailored to the individual needs of patients. Personalized treatment plans based on genetic profiles allow for more effective interventions and minimize the risks of adverse reactions. This shift toward precision medicine is expected to drive the future growth of the market.

Market Analysis

Drug Type Segmentation: The market for hereditary angioedema therapeutics can be segmented by drug type into C1-esterase inhibitors, bradykinin B2 receptor antagonists, kallikrein inhibitors, and others. C1-esterase inhibitors are the most widely used drugs for HAE treatment, both for acute attacks and long-term prophylaxis. However, new drugs, such as bradykinin B2 receptor antagonists and kallikrein inhibitors, are emerging as alternatives and are expected to play a significant role in the market's growth. These newer drugs offer enhanced efficacy, safety, and convenience compared to traditional treatments.

Route of Administration Segmentation: The therapeutic market is also segmented by the route of administration, with parenteral (injection or infusion) and oral drugs being the main categories. Parenteral treatments, such as C1-esterase inhibitors and kallikrein inhibitors, are commonly used for acute HAE attacks. However, oral therapies are gaining popularity due to their convenience, as they allow for at-home administration, which enhances patient compliance. The increasing availability of oral options for long-term prophylaxis is expected to further accelerate the adoption of these therapies.

Breakup by Drug Type

C1-Esterase Inhibitors: These are the first-line treatment options for hereditary angioedema. They work by replenishing the missing or defective C1 inhibitor, thereby preventing swelling episodes.

Bradykinin B2 Receptor Antagonists: Drugs in this category block the action of bradykinin, a protein that plays a key role in triggering swelling during an HAE attack.

Kallikrein Inhibitors: These inhibitors target kallikrein, an enzyme that contributes to the production of bradykinin. By inhibiting kallikrein, these drugs reduce the likelihood of HAE attacks.

Others: This category includes emerging therapies such as monoclonal antibodies and gene therapies, which are still under development or in early stages of use.

Breakup by Route of Administration

Parenteral: Parenteral drugs, delivered through injections or infusions, are essential for treating acute HAE attacks and providing emergency relief. These treatments are typically administered in healthcare settings or at home with proper training.
Oral: Oral drugs are becoming increasingly popular, especially for long-term prophylaxis. Oral therapies provide patients with greater flexibility and convenience, as they can be taken at home without the need for injections or hospital visits.
Regional Insights

United States

The United States is the largest market for hereditary angioedema therapeutics due to its well-established healthcare infrastructure, high healthcare expenditure, and advanced research in rare diseases. The increasing number of diagnosed cases, coupled with favorable regulatory policies, has positioned the U.S. as the leading market for HAE treatments. Additionally, the presence of major pharmaceutical companies and the availability of innovative therapies have further supported the market's growth. As awareness and diagnosis rates continue to rise, demand for effective treatment options is expected to increase in the coming years.

Canada

While smaller than the U.S. market, Canada's hereditary angioedema therapeutics market is growing steadily. The country benefits from a robust healthcare system and government initiatives to support the treatment of rare diseases. The adoption of novel therapies and advancements in genetic testing are driving increased patient awareness and better treatment outcomes. Canada is expected to see growth in HAE diagnosis and therapeutic treatment adoption, particularly as new treatment options become available.

Market Growth

Several factors are contributing to the growth of the hereditary angioedema therapeutics market in the U.S. The increasing prevalence of HAE, coupled with advancements in targeted therapies, is driving the demand for new and improved treatment options. The growing availability of both acute and prophylactic treatments is enhancing patient quality of life and compliance. Furthermore, the rising awareness of hereditary angioedema and the development of personalized medicine are expected to provide significant growth opportunities for market players in the coming years.

Recent Developments & Challenges

FDA Approval of New Treatments: Recent FDA approvals for novel therapies, including bradykinin B2 receptor antagonists and kallikrein inhibitors, have significantly expanded treatment options for HAE patients.

Advances in Gene Therapy: Gene therapy holds great promise for treating hereditary angioedema. Ongoing research into gene therapies that address the root cause of HAE could revolutionize the way the condition is managed.

Increased Patient Access: Expanding insurance coverage and healthcare programs have improved patient access to critical HAE treatments. This is crucial in ensuring that more patients can receive timely treatment and reduce the frequency of attacks.

Challenges in Diagnosis: Despite increased awareness, diagnosing hereditary angioedema remains challenging, as its symptoms can be mistaken for other conditions. Improved diagnostic tools are necessary to address this gap.

Key Players

Takeda Pharmaceutical Company Limited: Takeda is a global leader in rare disease treatments, including those for hereditary angioedema. The company's offerings include prophylactic and acute treatment options for HAE, such as Takhzyro, a bradykinin B2 receptor antagonist. Takeda is committed to improving patient outcomes through ongoing innovation and research into novel therapies for HAE.

BioCryst Pharmaceuticals, Inc.: BioCryst Pharmaceuticals is known for its development of oral therapies for HAE, including Orladeyo (berotralstat), a kallikrein inhibitor. This drug offers patients a convenient, at-home treatment option for long-term prophylaxis of HAE. BioCryst is dedicated to advancing its pipeline of therapies to address unmet needs in the rare disease space.

Sanofi: Sanofi's portfolio for hereditary angioedema includes treatments like Kalbitor (ecallantide), an injectable kallikrein inhibitor for acute attacks. Sanofi continues to research and develop new therapies to improve the lives of patients with HAE, with an emphasis on long-term prophylactic treatments.

CSL Behring LLC: CSL Behring is a key player in the HAE therapeutics market, offering products like Berinert, a C1-esterase inhibitor used to treat acute HAE attacks. The company's extensive portfolio includes both intravenous and subcutaneous therapies, catering to diverse patient needs.

Other: notable companies in the hereditary angioedema therapeutics market include Pharming Group N.V., Cipla, Inc., Ionis Pharmaceuticals Inc., Attune Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., Arrowhead Pharmaceuticals, Inc., and Pharvaris B.V.

FAQs

Q: What is hereditary angioedema? Hereditary angioedema is a rare genetic disorder that causes episodes of swelling in various parts of the body. It is due to a deficiency or dysfunction of C1-inhibitor, which regulates inflammation in the body.

Q: How is hereditary angioedema treated? HAE is treated with medications that prevent or reduce the severity of swelling attacks. These treatments include C1-esterase inhibitors, kallikrein inhibitors, bradykinin B2 receptor antagonists, and others.

Q: What is the prognosis for individuals with hereditary angioedema? With proper treatment, individuals with hereditary angioedema can manage their symptoms effectively and lead normal lives. Early diagnosis and tailored therapies are crucial for better outcomes.

Q: Which treatments are most effective for hereditary angioedema? The effectiveness of treatment varies depending on the patient's needs. C1-esterase inhibitors remain the first-line treatment, but newer options such as kallikrein inhibitors and bradykinin B2 receptor antagonists are also proving highly effective.

More Related Report:

Top 8 Viral Inactivation Firms: https://shorturl.at/Ge35c

Global Vessel Sealing Device Market: https://shorturl.at/xnZ22

Top 7 Pediatric Medical Device Companies & Manufacturers Worldwide: https://rb.gy/npfor4

Top 7 Spectrophotometer Companies in the Global Market: https://rb.gy/whkpif

India Healthcare Investment Surge: https://shorturl.at/8ClQT

Media Contact:

Company Name: Claight Corporation
Contact Person: Harry William, Corporate Sales Specialist - U.S.A.
Email: sales@expertmarketresearch.com
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: https://www.expertmarketresearch.com

About Us:

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Our high-quality, data-driven analysis provides the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today's competitive market.

Don't miss the opportunity to elevate your business intelligence and strengthen your strategic planning. Secure your organisation's future success by acquiring one of our Expert Market Research reports today.

This release was published on openPR.